MindWalk Holdings (HYFT) Liabilities and Shareholders Equity (2020 - 2026)
MindWalk Holdings (HYFT) reported Liabilities and Shareholders Equity of $16.6 million for Q1 2026, down 48.36% year-over-year from $32.1 million in Q1 2025, and down 11.97% quarter-over-quarter from $18.8 million in Q4 2025.
MindWalk Holdings (HYFT) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $16.6 million in Q1 2026.
- Liabilities and Shareholders Equity for Q1 2026 came in at $16.6 million, down 48.36% year-over-year; the trailing twelve-month figure through Jan 2026 was $96.3 million (down 41.13% YoY), and the FY2025 annual result was $31.9 million, down 27.89% from the prior year.
- Liabilities and Shareholders Equity fell to $16.6 million in Q1 2026 per HYFT's latest filing, from $18.8 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $73.9 million in Q2 2022 and troughed at $16.6 million in Q1 2026.
- A 5-year average of $46.6 million and a median of $44.6 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity surged 39.02% in 2022, then plunged 57.15% in 2025.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $62.3 million in 2022, then dropped by 10.5% to $55.8 million in 2023, then retreated by 21.25% to $43.9 million in 2024, then sank by 57.15% to $18.8 million in 2025, then fell by 11.97% to $16.6 million in 2026.
- Business Quant data shows HYFT's Liabilities and Shareholders Equity at $16.6 million in Q1 2026, $18.8 million in Q4 2025, and $29.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 33.89 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | 23.64 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 640.56 Mn |
| 10 | MindWalk Holdings | 166.20 Mn | 156.06 Mn | 1.78 | 16.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | 16.56 Mn |
| Oct 31, 2025 | 18.82 Mn |
| Jul 31, 2025 | 29.66 Mn |
| Apr 30, 2025 | 31.23 Mn |
| Jan 31, 2025 | 32.08 Mn |
| Oct 31, 2024 | 43.91 Mn |
| Jul 31, 2024 | 43.31 Mn |
| Apr 30, 2024 | 44.24 Mn |
| Jan 31, 2024 | 58.21 Mn |
| Oct 31, 2023 | 55.76 Mn |
| Jul 31, 2023 | 57.38 Mn |
| Apr 30, 2023 | 57.51 Mn |
| Jan 31, 2023 | 61.12 Mn |
| Oct 31, 2022 | 62.31 Mn |
| Jul 31, 2022 | 62.16 Mn |
| Apr 30, 2022 | 73.94 Mn |
| Jan 31, 2022 | 44.60 Mn |
| Oct 31, 2021 | 47.99 Mn |
| Jul 31, 2021 | 52.45 Mn |
| Apr 30, 2021 | 53.19 Mn |